Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease

Ken Ichiro Tanaka, Shota Kurotsu, Teita Asano, Naoki Yamakawa, Daisuke Kobayashi, Yasunobu Yamashita, Hiroshi Yamazaki, Tomoaki Ishihara, Hiroshi Watanabe, Toru Maruyama, Hidekazu Suzuki, Tohru Mizushima

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We recently proposed that mepenzolate bromide (mepenzolate) would be therapeutically effective against chronic obstructive pulmonary disease (COPD) due to its both anti-inflammatory and bronchodilatory activities. In this study, we examined the benefits and adverse effects associated with different routes of mepenzolate administration in mice. Oral administration of mepenzolate caused not only bronchodilation but also decreased the severity of elastase-induced pulmonary emphysema; however, compared with the intratracheal route of administration, about 5000 times higher dose was required to achieve this effect. Intravenously or intrarectally administered mepenzolate also showed these pharmacological effects. The intratracheal route of mepenzolate administration, but not other routes, resulted in protective effects against elastase-induced pulmonary damage and bronchodilation at a much lower dose than that which affected defecation and heart rate. These results suggest that the pulmonary route of mepenzolate administration may be superior to other routes (oral, intravenous or intrarectal) to treat COPD patients.

Original languageEnglish
Article number04510
JournalScientific Reports
Volume4
DOIs
Publication statusPublished - 2014 Mar 28

Fingerprint

Chronic Obstructive Pulmonary Disease
Lung
Pancreatic Elastase
Therapeutics
Pulmonary Emphysema
Defecation
mepenzolic acid
Oral Administration
Anti-Inflammatory Agents
Heart Rate
Pharmacology

ASJC Scopus subject areas

  • General

Cite this

Tanaka, K. I., Kurotsu, S., Asano, T., Yamakawa, N., Kobayashi, D., Yamashita, Y., ... Mizushima, T. (2014). Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease. Scientific Reports, 4, [04510]. https://doi.org/10.1038/srep04510

Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease. / Tanaka, Ken Ichiro; Kurotsu, Shota; Asano, Teita; Yamakawa, Naoki; Kobayashi, Daisuke; Yamashita, Yasunobu; Yamazaki, Hiroshi; Ishihara, Tomoaki; Watanabe, Hiroshi; Maruyama, Toru; Suzuki, Hidekazu; Mizushima, Tohru.

In: Scientific Reports, Vol. 4, 04510, 28.03.2014.

Research output: Contribution to journalArticle

Tanaka, KI, Kurotsu, S, Asano, T, Yamakawa, N, Kobayashi, D, Yamashita, Y, Yamazaki, H, Ishihara, T, Watanabe, H, Maruyama, T, Suzuki, H & Mizushima, T 2014, 'Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease', Scientific Reports, vol. 4, 04510. https://doi.org/10.1038/srep04510
Tanaka, Ken Ichiro ; Kurotsu, Shota ; Asano, Teita ; Yamakawa, Naoki ; Kobayashi, Daisuke ; Yamashita, Yasunobu ; Yamazaki, Hiroshi ; Ishihara, Tomoaki ; Watanabe, Hiroshi ; Maruyama, Toru ; Suzuki, Hidekazu ; Mizushima, Tohru. / Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease. In: Scientific Reports. 2014 ; Vol. 4.
@article{3dd7f35477cc4e4aa704984a7f9ccb1a,
title = "Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease",
abstract = "We recently proposed that mepenzolate bromide (mepenzolate) would be therapeutically effective against chronic obstructive pulmonary disease (COPD) due to its both anti-inflammatory and bronchodilatory activities. In this study, we examined the benefits and adverse effects associated with different routes of mepenzolate administration in mice. Oral administration of mepenzolate caused not only bronchodilation but also decreased the severity of elastase-induced pulmonary emphysema; however, compared with the intratracheal route of administration, about 5000 times higher dose was required to achieve this effect. Intravenously or intrarectally administered mepenzolate also showed these pharmacological effects. The intratracheal route of mepenzolate administration, but not other routes, resulted in protective effects against elastase-induced pulmonary damage and bronchodilation at a much lower dose than that which affected defecation and heart rate. These results suggest that the pulmonary route of mepenzolate administration may be superior to other routes (oral, intravenous or intrarectal) to treat COPD patients.",
author = "Tanaka, {Ken Ichiro} and Shota Kurotsu and Teita Asano and Naoki Yamakawa and Daisuke Kobayashi and Yasunobu Yamashita and Hiroshi Yamazaki and Tomoaki Ishihara and Hiroshi Watanabe and Toru Maruyama and Hidekazu Suzuki and Tohru Mizushima",
year = "2014",
month = "3",
day = "28",
doi = "10.1038/srep04510",
language = "English",
volume = "4",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease

AU - Tanaka, Ken Ichiro

AU - Kurotsu, Shota

AU - Asano, Teita

AU - Yamakawa, Naoki

AU - Kobayashi, Daisuke

AU - Yamashita, Yasunobu

AU - Yamazaki, Hiroshi

AU - Ishihara, Tomoaki

AU - Watanabe, Hiroshi

AU - Maruyama, Toru

AU - Suzuki, Hidekazu

AU - Mizushima, Tohru

PY - 2014/3/28

Y1 - 2014/3/28

N2 - We recently proposed that mepenzolate bromide (mepenzolate) would be therapeutically effective against chronic obstructive pulmonary disease (COPD) due to its both anti-inflammatory and bronchodilatory activities. In this study, we examined the benefits and adverse effects associated with different routes of mepenzolate administration in mice. Oral administration of mepenzolate caused not only bronchodilation but also decreased the severity of elastase-induced pulmonary emphysema; however, compared with the intratracheal route of administration, about 5000 times higher dose was required to achieve this effect. Intravenously or intrarectally administered mepenzolate also showed these pharmacological effects. The intratracheal route of mepenzolate administration, but not other routes, resulted in protective effects against elastase-induced pulmonary damage and bronchodilation at a much lower dose than that which affected defecation and heart rate. These results suggest that the pulmonary route of mepenzolate administration may be superior to other routes (oral, intravenous or intrarectal) to treat COPD patients.

AB - We recently proposed that mepenzolate bromide (mepenzolate) would be therapeutically effective against chronic obstructive pulmonary disease (COPD) due to its both anti-inflammatory and bronchodilatory activities. In this study, we examined the benefits and adverse effects associated with different routes of mepenzolate administration in mice. Oral administration of mepenzolate caused not only bronchodilation but also decreased the severity of elastase-induced pulmonary emphysema; however, compared with the intratracheal route of administration, about 5000 times higher dose was required to achieve this effect. Intravenously or intrarectally administered mepenzolate also showed these pharmacological effects. The intratracheal route of mepenzolate administration, but not other routes, resulted in protective effects against elastase-induced pulmonary damage and bronchodilation at a much lower dose than that which affected defecation and heart rate. These results suggest that the pulmonary route of mepenzolate administration may be superior to other routes (oral, intravenous or intrarectal) to treat COPD patients.

UR - http://www.scopus.com/inward/record.url?scp=84897137681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897137681&partnerID=8YFLogxK

U2 - 10.1038/srep04510

DO - 10.1038/srep04510

M3 - Article

VL - 4

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 04510

ER -